BCR and chronic myelogenous leukemia, BCR-ABL1 positive: We excluded patients who had only a single BCR::ABL1 measurement throughout their observation period and those not prescribed tyrosine kinase inhibitors (TKIs), the standard first-line therapy for CML that suppresses BCR::ABL1 activity and drives molecular response.